ASCO 2025 - Liste complète des programmes (18)

Série complète des revues quotidiennes et des interviews de ASCO 2025

POST ASCO

Le Dr Jean-Pierre Ayoub met en lumière trois résumés marquants de l’ASCO 2025 — ASCENT-04, DESTINY-Breast09 et INAVO120 — en partageant les résultats clés en cancer du sein métastatique qui influencent déjà sa pratique clinique.

Dr. Paolo Tarantino highlights practice-changing data from ASCO 2025, including key insights from DESTINY-Breast09, ASCENT-04, and SERENA-6, with reflections on their clinical implications in breast cancer care.

Dr. Xiaofu Zhu shares his takeaways from ASCO 2025, highlighting standout abstracts and practice-changing findings across multiple breast cancer subtypes, and reflecting on the most significant developments from the congress.

Dr. Kevin Kalinsky shares key findings from the NATALEE trial, highlighting how ribociclib outcomes differ by age and menopausal status in HR+/HER2- early breast cancer. Insights highlight implications for personalized treatment.

La Dre Kim Ma met en lumière les données clés présentées lors de la dernière journée de l’ASCO 2025 sur le cancer du sein localisé, en abordant les thèmes émergents de la thérapie néoadjuvante HER2, de la gestion des ganglions lymphatiques en chirurgie, et du rôle croissant de la suppression ovarienne.

Le Dr Nagi El Saghir résume les points clés de l’ASCO 2025, partage les enseignements de sa présentation sur l’analyse de sous-groupes de l’étude RIGHT Choice, et revient sur les essais majeurs : INAVO120, SERENA-6, VERITAC-2 et DESTINY-Breast09.

La Dre Kim Ma partage ses réflexions post-ASCO sur l’évolution de l’hormonothérapie dans le cancer du sein métastatique RH+, en mettant en lumière des avancées prometteuses qui redéfinissent les stratégies de traitement.

Dr. Ana Lohmann reviews her ASCO 2025 poster on recurrence patterns across breast cancer subtypes in the CCTG MA.32 trial, highlighting the ongoing risk of late recurrence in luminal BC and persistent risk of second primaries in all breast cancer subtypes .

Dr. Angela Toss reviews findings from an international cohort study presented at ASCO 2025, exploring how different types of BRCA1/2 pathogenic or likely pathogenic variants impact outcomes in young patients with breast cancer.

Dr. Marina De Brot presents their work showcased at ASCO 2025 on using AI to improve detection of HER2-low and HER2-ultralow breast cancer, enhancing diagnostic accuracy and expanding eligibility for HER2-targeted treatments.

Dr. Tara Sanft discusses findings from the BCI Registry Study presented at ASCO 2025, highlighting how the Breast Cancer Index influences treatment decisions in a prospective real-world setting.

Dr. Susan Dent reviews data impacting women with advanced breast cancer, comparing interim results from DESTINY-Breast09 to the CLEOPATRA standard. She addresses questions around time on therapy, practice change, and the importance of individualized, patient-centered care.

Drs. Jamil Asselah and Kim Ma return to discuss the latest ASCO 2025 data, focusing on SERENA-6 PFS outcomes and DESTINY-Breast09, where T-DXd plus pertuzumab sets a new first-line standard in HER2+ mBC with practice-changing impact.

Dr. Jamil Asselah speaks with Dr. David Cescon about results from the ASCENT-04 trial presented at ASCO 2025, discussing current standards of care, safety data, and the impact of these findings on clinical practice.

Drs. Jamil Asselah and Pedro Moraes review key data from SERENA-6 and ASCENT-04 presented at ASCO 2025, discussing whether the results are practice-changing and reflecting on their impact and interpretation from a global perspective.

Prof. Rebecca Dent highlights practice-changing data from ASCO 2025, including emerging therapies with different side effect profiles and new monitoring strategies in ER+ mBC. She reflects on the SERENA-6 plenary not just as data, but as a concept shaping the future of care, and shares key takeaways from her own DB-06 biomarker analysis of T-DXd vs TPC.

Dr. Susan Dent highlights her focus on cardiovascular health in breast cancer care, reviewing ASCO 2025 data on cardiotoxicities linked to modern cancer therapies and the need for proactive cardio-oncology strategies.

Les Drs Jamil Asselah et Kim Ma reviennent sur le jour 1 de l’ASCO 2025, marqué par une forte focalisation sur le cancer du sein à récepteurs hormonaux positifs, en mettant en lumière les nouvelles données de survie de l’essai INAVO120 et les perspectives pour le jour 2.